MRTX1133

AXP000026.1 · Targeted small molecule

Platform
small molecule
Targets
KRAS
Originator
Mirati Therapeutics
Sponsor
Bristol Myers Squibb

Names

NameTypeSource
MRTX1133preferred name, codecurator, ncit

Cross-references

NCI Thesaurus
C200319
FDA UNII
DU32DM9CHD

Approvals

No regulatory approval recorded.

Clinical trials (1)

TrialTitleStatusPhaseStartPrimary completionEnrolmentConditions
NCT05737706Study of MRTX1133 in Patients With Advanced Solid Tumors Harboring a KRAS G12D MutationTerminatedPhase 12023-03-062025-03-1063Advanced Solid Tumor; Colo-rectal Cancer; Non-small Cell Lung Cancer; Pancreatic Adenocarcinoma; Solid Tumor

Recent changes

No changes recorded in its trials yet.

Clinical papers

PubMedTitleJournalYearLinked by
PMID 40740271Rare Case of Duodenal Metastasis From Colon Cancer: Review of Literature and Insights on Novel Therapies.Case reports in gastrointestinal medicine2025name in abstract: MRTX1133

Other papers

Preclinical studies, reviews and other papers that name it, newest 100 shown.

PubMedTitleJournalYearLinked by
PMID 41129140Dual Inhibitors of KRASG12D and HSP90 Are Effective against KRASG12D Inhibitor Resistance.Molecular cancer therapeutics2026name in abstract: MRTX1133
PMID 41379561HDAC5 deficiency induces intrinsic resistance to KRAS inhibition by disrupting c-Myc acetylation-ubiquitination homeostasis.The Journal of clinical investigation2026name in abstract: MRTX1133
PMID 41419408Targeted and immunotherapy strategies in pancreatic ductal adenocarcinoma: Recent developments and insights.Hepatobiliary & pancreatic diseases international : HBPD INT2026name in abstract: MRTX1133
PMID 41432073Discovery of Pyrazoloquinazoline Analogues as Orally Bioavailable KRAS-G12D Inhibitors.Journal of medicinal chemistry2026name in abstract: MRTX1133
PMID 41456631Dual Inhibition of KRAS G12D and PI3K/BRD4 signaling overcomes therapeutic resistance in pancreatic cancer.Acta biomaterialia2026name in abstract: MRTX1133
PMID 41501279Antimetastatic effects of MRTX1133 KRAS G12D specific inhibitor in a liver metastatic model of pancreatic ductal adenocarcinoma.Scientific reports2026name in title: MRTX1133
PMID 41506251In-Source Fragmentation of Pyrrolidine-Containing KRAS Scaffolds Leads to Enhanced Structure Elucidation and Tandem Mass Spectral Quality.Journal of the American Society for Mass Spectrometry2026name in abstract: MRTX1133
PMID 41513443KRAS mutation-driven O-GlcNAcylation of CLDN18.2 enhances the progression of pancreatic cancer and reduces the efficacy of CLDN18.2-targeted therapy.Gut2026name in abstract: MRTX1133
PMID 41519889Structure of SHOC2-KRAS-PP1C complex reveals RAS isoform-specific determinants and insights into targeting complex assembly by RAS inhibitors.Nature communications2026name in abstract: MRTX1133
PMID 41527355Resistance to the KRASG12D Inhibitor MRTX1133 Is Associated with Increased Sensitivity to BET Inhibition.Molecular cancer therapeutics2026name in title: MRTX1133
PMID 41542622The combination of BCL-xL PROTAC and mTOR inhibitor sensitizes pancreatic ductal adenocarcinoma to KRASG12D inhibitor treatment by enhancing apoptosis induction.bioRxiv : the preprint server for biology2026name in abstract: MRTX1133
PMID 41556452Ferritin-based nanocarrier delivery of KRAS G12D inhibitor in pancreatic adenocarcinoma cells and patient-derived organoids: A novel approach for treatment.Protein science : a publication of the Protein Society2026name in abstract: MRTX1133
PMID 41604371Computational repurposing of approved drugs targeting KRAS G12D and EGFR for colorectal cancer therapy.PloS one2026name in abstract: MRTX1133
PMID 41636798Exploring the GDP binding to KRas WT, G12C, G12D, G12R, and G12V and bound with MRTX1133 using steered molecular dynamics.European biophysics journal : EBJ2026name in title: MRTX1133
PMID 41679196Discovery of KRAS-G12D degraders via exploration of various E3 ligases.European journal of medicinal chemistry2026name in abstract: MRTX1133
PMID 41722442FGTI-2734 prevents ERK-mediated resistance and enhances MRTX1133 efficacy in KRAS G12D pancreatic cancer.European journal of cancer (Oxford, England : 1990)2026name in title: MRTX1133
PMID 41735281Combination of PARP and KRASG12D inhibitors enhances therapeutic efficacy by exploiting vulnerabilities in PDAC.Nature communications2026name in abstract: MRTX1133
PMID 41813757Screening of kinase inhibitors in the triple negative KRAS G13D-mutated MDA-MB-231 breast cancer cell line.Scientific reports2026name in abstract: MRTX1133
PMID 41816298Pharmaco-genomic characterization of pancreatic and biliary tract cancer tumoroids for drug response.iScience2026name in abstract: MRTX1133
PMID 41822354Tumor microenvironment-activated ferritin nanovector enables enhanced tumor delivery of KRASG12C inhibitors and degraders.Frontiers in cell and developmental biology2026name in abstract: MRTX1133
PMID 41830517MRTX1133 suppresses ERK signaling but elicits context-dependent antiproliferative responses in KRAS (G12C) cancer cells.Molecular cancer therapeutics2026name in title: MRTX1133
PMID 41899524The Combination of a BCL-xL PROTAC and an mTOR Inhibitor Sensitizes Pancreatic Ductal Adenocarcinoma to KRASG12D Inhibitor Treatment.Cancers2026name in abstract: MRTX1133
PMID 41951768High-throughput screening identifies NT-1 that synergizes with MRTX1133 against acquired resistant KRASG12D colorectal cancer.NPJ precision oncology2026name in title: MRTX1133
PMID 41969551Emerging KRAS G12D inhibitor in the treatment of digestive system tumors: opportunities and challenges.Translational gastroenterology and hepatology2026name in abstract: MRTX1133
PMID 41993359KRAS inhibition is an effective therapy for appendiceal adenocarcinoma.bioRxiv : the preprint server for biology2026name in abstract: MRTX1133
PMID 42030031GAP mimetic activity of pan-Ras TCI daraxonrasib synergizes with K-Ras Switch-II pocket inhibition.Biological chemistry2026name in abstract: MRTX1133
PMID 42038352KRAS (G12D)-selective inhibitor MRTX1133 suppresses proliferation and differentially modulates chemosensitivity in ovarian mucinous carcinoma.Oncology letters2026name in title: MRTX1133
PMID 42041157MRTX1133 Suppresses ERK Signaling but Elicits Context-Dependent Antiproliferative Responses in KRAS (G12C) Cancer Cells.Molecular cancer therapeutics2026name in title: MRTX1133
PMID 42054368Fra-2 controls the response to the KRAS inhibitor MRTX-1133 in pancreatic ductal adenocarcinoma.Proceedings of the National Academy of Sciences of the United States of America2026name in title: MRTX1133
PMID 42079131Characterization and therapeutic suppression of KEAP1-NRF2-driven resistance to KRAS inhibitors in pancreatic and lung cancer.bioRxiv : the preprint server for biology2026name in abstract: MRTX1133
PMID 42126708Identification of natural compounds targeting the KRAS G12D mutation in pancreatic cancer through integrated in silico and in vitro approaches.Journal of computer-aided molecular design2026name in abstract: MRTX1133
PMID 42191046Targeting Oncomucin-Driven Immunosuppression Improves the Efficacy of K-rasG12D Inhibition in Pancreatic Cancer.Gastroenterology2026name in abstract: MRTX1133
PMID 42198429A Molecular-Protein Fusion Framework for Rapid Virtual Screening: Accelerating Lead Discovery for "Undruggable'' Oncogenic Targets.Pharmaceuticals (Basel, Switzerland)2026name in abstract: MRTX1133
PMID 42209458Efficacy of dual KRASG12D-EGFR blockade versus triple combinations in patient-derived models of KRASG12D-mutant colorectal cancer.Cell death & disease2026name in abstract: MRTX1133
PMID 42221851Stability-Driven Pose Prediction and Ligand Design via Contact Persistence Analysis from Molecular Dynamics Simulations.Computational and structural biotechnology journal2026name in abstract: MRTX1133
PMID 42259905Variable efficacy of the non-covalent KRASG12D inhibitor (MRTX-1133) with obesity in murine pancreatic cancer.NPJ precision oncology2026name in title: MRTX1133
PMID 42298062Targeting WFS1 overcomes KRASG12D dependency and adaptive resistance to KRAS inhibition in pancreatic cancer.NPJ precision oncology2026name in abstract: MRTX1133
PMID 42321850Palbociclib targets β-catenin for degradation and synergizes with KRAS or ERK5 inhibition in colorectal cancer preclinical models.Journal of translational medicine2026name in abstract: MRTX1133
PMID 42392864USP20 promotes CD8+ T cell exhaustion and impairs KRASG12D inhibitor efficacy by orchestrating cholesterol metabolism and autophagy in pancreatic cancer.Gut2026name in abstract: MRTX1133
PMID 42393724KRAS inhibition is an effective therapy for appendiceal adenocarcinoma.Journal of hematology & oncology2026name in abstract: MRTX1133
PMID 42398486In Silico identification of natural and synthetic inhibitors targeting KRAS mutants (G12D, G12V, and G12C) and wild-type in pancreatic cancer.Journal of molecular graphics & modelling2026name in abstract: MRTX1133
PMID 42399085Dysregulated sphingolipid metabolismdrives pancreatic carcinogenesis through plasma membrane Kras enrichment.Gut2026name in abstract: MRTX1133
PMID 42436354CDK8 remodels the tumor microenvironment and promotes resistance to KRASG12D inhibitors and daraxonrasib in PDAC.The EMBO journal2026name in abstract: MRTX1133
PMID 42490421KRASG12D inhibition reprograms the tumor-induced immunosuppressive environment and enhances NK cell-mediated antitumor immunity.Science advances2026name in abstract: MRTX1133
PMID 42523398Concurrent Stereotactic Body Radiation Therapy and KRAS Inhibition Synergistically Improve Pre-clinical Pancreatic Cancer Treatment.bioRxiv : the preprint server for biology2026name in abstract: MRTX1133
PMID 42580447Targeted KRAS suppression in colorectal cancer via in vivo self-assembled siRNAs encapsulated in endogenous small extracellular vesicles.Journal of controlled release : official journal of the Controlled Release Society2026name in abstract: MRTX1133
PMID 42603637Discovery of a Potent and Selective KRAS G12D Degrader based on PROTAC Degradation.European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences2026name in abstract: MRTX1133
PMID 42615854Progress and challenges in the design and development of selective KRAS G12D-targeted drug discovery: inhibitors, degraders and emerging therapeutic strategies.Future medicinal chemistry2026name in abstract: MRTX1133
PMID 42649211Oncogenic Kras targeting with MRTX1133 or Daraxonrasib specifically synergize with anti-CTLA4 to promote anti-tumor immunity in pancreatic cancer.Nature communications2026name in title: MRTX1133
PMID 42667948XPO1 inhibition enhances the efficacy and durability of RAS-targeted therapy in preclinical models of KRASG12D mutant pancreatic ductal adenocarcinoma.Cancer letters2026name in abstract: MRTX1133
PMID 42678463Emerging Therapeutic Strategies for Non-G12C KRAS Mutations in Colorectal Cancer: Focusing on G12D and G12V.Journal of gastrointestinal cancer2026name in abstract: MRTX1133
PMID 42693727Identification of the Potential of Plant-Derived Agents to Act as KRAS G12D Inhibitors Through Molecular Docking, Molecular Dynamics Simulations, and MMGBSA.Current pharmaceutical design2026name in abstract: MRTX1133
PMID 42720810Beyond KRASG12C: emerging therapeutic strategies, patent landscape, and clinical progress in targeting KRAS-mutant cancers.Medical oncology (Northwood, London, England)2026name in abstract: MRTX1133
PMID 42771504IRE1α-XBP1s signaling links lipid homeostasis to hypoxic maladaptation and KRAS inhibitor responses in pancreatic ductal adenocarcinoma.Proceedings of the National Academy of Sciences of the United States of America2026name in abstract: MRTX1133
PMID 42841489Variant-selective and pan-RAS inhibitors enhance targeted agent activity in patient-derived multi-cell type tumor spheroids.Molecular cancer therapeutics2026name in abstract: MRTX1133
PMID 42956743KRASG12D-targeted therapy sensitivity depends on interferon signaling activation in pancreatic cancer.Cancer cell2026name in abstract: MRTX1133
PMID 42971499Saturation mutagenesis library screening identifies on-target secondary resistance mutations in KRASG12D-selective inhibitors.Cancer letters2026name in abstract: MRTX1133
PMID 42984346Variant-Selective and Pan-RAS Inhibitors Enhance Targeted Agent Activity in Patient-Derived Multi-cell-type Tumor Spheroids.Molecular cancer therapeutics2026name in abstract: MRTX1133
PMID 42988458Simultaneous LC-MS/MS quantification of four KRAS inhibitors (RMC-6236, RMC-9805, RMC-7977, and MRTX1133) in human plasma: toward therapeutic drug monitoring in pancreatic ductal adenocarcinoma.Bioanalysis2026name in title: MRTX1133
PMID 39400496Targeting KRAS-mutant pancreatic cancer through simultaneous inhibition of KRAS, MEK, and JAK2.Molecular oncology2025name in abstract: MRTX1133
PMID 39651222Multimetric MRI Captures Early Response and Acquired Resistance of Pancreatic Cancer to KRAS Inhibitor Therapy.bioRxiv : the preprint server for biology2025name in abstract: MRTX1133
PMID 39657309MRTX1133 attenuates KRASG12D mutated-colorectal cancer progression through activating ferroptosis activity via METTL14/LINC02159/FOXC2 axis.Translational oncology2025name in title: MRTX1133
PMID 39664928Dynamic conformational equilibria in the active states of KRAS and NRAS.RSC chemical biology2025name in abstract: MRTX1133
PMID 39710177Decoding KRAS dynamics: Exploring the impact of mutations and inhibitor binding.Archives of biochemistry and biophysics2025name in abstract: MRTX1133
PMID 39786607Development of a new flippase-dependent mouse model for red fluorescence-based isolation of KRASG12D oncogene-expressing tumor cells.Transgenic research2025name in abstract: MRTX1133
PMID 39810420Pancreatic cancer-derived extracellular vesicles enhance chemoresistance by delivering KRASG12D protein to cancer-associated fibroblasts.Molecular therapy : the journal of the American Society of Gene Therapy2025name in abstract: MRTX1133
PMID 39879317AGER-dependent macropinocytosis drives resistance to KRAS-G12D-targeted therapy in advanced pancreatic cancer.Science translational medicine2025name in abstract: MRTX1133
PMID 39970873KRASG12D-driven pentose phosphate pathway remodeling imparts a targetable vulnerability synergizing with MRTX1133 for durable remissions in PDAC.Cell reports. Medicine2025name in title: MRTX1133
PMID 40073053SOS1 inhibitor BI-3406 shows in vivo antitumor activity akin to genetic ablation and synergizes with a KRASG12D inhibitor in KRAS LUAD.Proceedings of the National Academy of Sciences of the United States of America2025name in abstract: MRTX1133
PMID 40082968ADT-1004: a first-in-class, oral pan-RAS inhibitor with robust antitumor activity in preclinical models of pancreatic ductal adenocarcinoma.Molecular cancer2025name in abstract: MRTX1133
PMID 40093186Distinct small molecule inhibitors of Kras specifically prime CTLA4 blockade therapy to transcriptionally reprogram Tregs and overcome resistance to suppress pancreas cancer.bioRxiv : the preprint server for biology2025name in abstract: MRTX1133
PMID 40146324Enhancing KRAS G12D inhibitor sensitivity in pancreatic cancer through SHP2/PI3K pathway.Medical oncology (Northwood, London, England)2025name in abstract: MRTX1133
PMID 40210129Combinatorial screen with apoptosis pathway targeted agents alrizomadlin, pelcitoclax, and dasminapant in multi-cell type tumor spheroids.SLAS discovery : advancing life sciences R & D2025name in abstract: MRTX1133
PMID 40260640Multimetric MRI Captures Early Response and Acquired Resistance of Pancreatic Cancer to KRAS Inhibitor Therapy.Clinical cancer research : an official journal of the American Association for Cancer Research2025name in abstract: MRTX1133
PMID 40268231Switch II Pocket Inhibitor Allosterically Freezes KRASG12D Nucleotide-binding Site and Arrests the GTPase Cycle.Journal of molecular biology2025name in abstract: MRTX1133
PMID 40382842KRAS inhibition reverses chemotherapy resistance promoted by therapy-induced senescence-like in pancreatic ductal adenocarcinoma.Translational oncology2025name in abstract: MRTX1133
PMID 40420168Targeting DNA helicase CMG complex and NFκB2-driven drug-resistant transcriptional axis to effectively treat KRASG12D-mutated pancreatic cancer.Experimental hematology & oncology2025name in abstract: MRTX1133
PMID 40430514Design, Synthesis, Anticancer Evaluation and Molecular Docking of Pyrimidine, Pyrido[4,3-d]pyrimidine and 5,6,7,8-Tetrahydropyrido[3,4-d]pyrimidine Derivatives as Novel KRAS-G12D Inhibitors and PROTACs.Pharmaceuticals (Basel, Switzerland)2025name in abstract: MRTX1133
PMID 40437561Acetylation-induced degradation of ECHS1 enhances BCAA accumulation and proliferation in KRAS-mutant colorectal cancer.Journal of experimental & clinical cancer research : CR2025name in abstract: MRTX1133
PMID 40439998Combination Therapy of Avutometinib and MRTX1133 Synergistically Suppresses Cell Growth by Inducing Apoptosis in KRASG12D-Mutated Pancreatic Cancer.Molecular cancer therapeutics2025name in title: MRTX1133
PMID 40463163Resistance to the KRASG12D Inhibitor MRTX1133 is Associated with Increased Sensitivity to BET Inhibition.bioRxiv : the preprint server for biology2025name in title: MRTX1133
PMID 40470182RNA processing kinase inhibitors and epigenetic inhibitors in combination with oncology drugs or investigational agents in multi-cell type patient-derived tumor cell line spheroids.Research square2025name in abstract: MRTX1133
PMID 40624835Drugging the 'undruggable' KRAS: breakthroughs, challenges, and opportunities in pancreatic cancer.Cancer biology & medicine2025name in abstract: MRTX1133
PMID 40631072High Throughput Screening Identifies Small Molecules that Synergize with MRTX1133 Against Acquired Resistant KRAS G12D Mutated CRC.bioRxiv : the preprint server for biology2025name in title: MRTX1133
PMID 40652232Investigation of potential KRASG12D inhibitors: a comparative study between MRTX1133 and natural compounds via computational structural biology approaches.BMC research notes2025name in title: MRTX1133
PMID 40666480Identification of Novel pan-KRAS Inhibitors via Structure-Based Drug Design, Scaffold Hopping, and Biological Evaluation.ACS medicinal chemistry letters2025name in abstract: MRTX1133
PMID 40743812The design and synthesis of selective and potent selenium-containing KRASG12D inhibitors.European journal of medicinal chemistry2025name in abstract: MRTX1133
PMID 40755231Co-targeting KRASG12D and the HER family is efficacious in colorectal cancer.Carcinogenesis2025name in abstract: MRTX1133
PMID 40780213A pan-KRAS inhibitor and its derived degrader elicit multifaceted anti-tumor efficacy in KRAS-driven cancers.Cancer cell2025name in abstract: MRTX1133
PMID 40791564CDK8 remodels the tumor microenvironment to resist the therapeutic efficacy of targeted KRAS G12D inhibition in pancreatic ductal adenocarcinoma.bioRxiv : the preprint server for biology2025name in abstract: MRTX1133
PMID 40800005CDCP1-targeting ADC outperforms standard therapies in Ras-mutant pancreatic cancer.Molecular therapy. Oncology2025name in abstract: MRTX1133
PMID 40805153Treatment of KRAS-Mutated Pancreatic Cancer: New Hope for the Patients?Cancers2025name in abstract: MRTX1133
PMID 40848084Simulating tumor complexity: 3D pancreatic tumor spheroid model for improved drug screening.Human cell2025name in abstract: MRTX1133
PMID 40886852Harmine suppresses pancreatic cancer through DYRK1A-mediated hyper-activated RAS/MAPK inhibition.Biochemical pharmacology2025name in abstract: MRTX1133
PMID 40938473RNA processing kinase inhibitors and epigenetic inhibitors in combination with oncology drugs or investigational agents in multi-cell type patient-derived tumor cell line spheroids.Cancer chemotherapy and pharmacology2025name in abstract: MRTX1133
PMID 40997784ZJK-807: A Selective PROTAC Degrader of KRASG12D Overcoming Resistance in Pancreatic Cancer.Journal of medicinal chemistry2025name in abstract: MRTX1133
PMID 41000780VEGFR2 blockade overcomes acquired KRAS G12D inhibitor resistance driven by PI3Kγ activation.bioRxiv : the preprint server for biology2025name in abstract: MRTX1133
PMID 41017113Expanding the Chemistry of Acyl Diazo Electrophile as a Tunable Warhead for Covalent Targeting of KRAS (G12D) Mutant.Journal of medicinal chemistry2025name in abstract: MRTX1133
PMID 41086055Targeting KRAS Inhibitor-Resistant Pancreatic Cancer with an MUC1-C Antibody-Drug Conjugate.Clinical cancer research : an official journal of the American Association for Cancer Research2025name in abstract: MRTX1133
PMID 41130420Hybrid nanovesicles enhance antitumor efficacy in KRAS-mutant non-small cell lung cancer.Journal of controlled release : official journal of the Controlled Release Society2025name in abstract: MRTX1133

NIH grants

ProjectTitleOrganisationPIYearsLinked by
F31CA309960Leveraging pIgR-mediated endocytosis of dimeric IgA in PDAC TreatmentUNIV OF NORTH CAROLINA CHAPEL HILLSILVA, HARRISON2026–2026name in abstract: MRTX1133
R01CA296410Optimization of an active mutant KRAS peptide vaccine in colorectal cancerJOHNS HOPKINS UNIVERSITYAZAD, NILOFER S.2025–2026name in abstract: MRTX1133
R01CA303154Interactive Functional Dynamics of Human K-Ras, Its Oncogenic Mutants and their Binding PartnersOHIO STATE UNIVERSITYBRUSCHWEILER, RAFAEL2026–2026name in abstract: MRTX1133
R21CA309360Identifying immune-mediated mechanisms of RAS inhibitor efficacy and resistance in pancreatic cancerUNIV OF NORTH CAROLINA CHAPEL HILLMILNER, JOHN JUSTIN2026–2026name in abstract: MRTX1133
R03CA304041Targeting the HER Family in KRAS Mutant Colorectal CancerUNIVERSITY OF CINCINNATIGARRETT, JOAN T.2025–2025name in abstract: MRTX1133
R21CA286372The Role of the Tumor Microenvironment in Resistance to Oncogenic KRAS Inhibition in Lung CancerUNIVERSITY OF MICHIGAN AT ANN ARBORGALBAN, STEFANIE2024–2025name in abstract: MRTX1133
R21CA297690Noncovalent interaction of mutant KRAS inhibitorsDUKE UNIVERSITYCHI, JEN-TSAN ASHLEY2025–2025name in abstract: MRTX1133

Notes

KRAS G12D non-covalent. No INN found. BMS reported discontinued (ApexOnco 2025-03-05). Reported discontinued by Bristol Myers Squibb (ApexOnco, 2025-03-05); kept because trials and papers use the name.

How to cite

MRTX1133 (AXP000026.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000026.html

Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.